Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka VPRIV

Velaglucerase alfa — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Velaglucerase alfa (also known as VPRIV) is a peptide catalogued under Enzymes (Gaucher). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Velaglucerase alfa?

Velaglucerase alfa (brand name VPRIV) is a recombinant human glucocerebrosidase (acid beta-glucosidase) used as enzyme replacement therapy for type 1 (non-neuronopathic) Gaucher disease.

It is approved by both the US FDA and the European Medicines Agency (2010) and is supported by multinational, randomized, double-blind Phase 3 trials, including a head-to-head comparison against imiglucerase.

This is an established, regulator-approved biologic with a robust human clinical-trial evidence base.

How does Velaglucerase alfa work?

Velaglucerase alfa replaces the deficient lysosomal enzyme glucocerebrosidase, which breaks down glucocerebroside (glucosylceramide) that otherwise accumulates in macrophages (Gaucher cells) in the spleen, liver and bone marrow.

It is produced by gene activation in a human cell line and carries terminal mannose residues that target uptake by macrophage mannose receptors.

What does the research say about Velaglucerase alfa?

  • In a randomized, double-blind Phase 3 trial, velaglucerase alfa increased hemoglobin and platelet counts and reduced liver and spleen volume in treatment-naive type 1 Gaucher disease. [1]
  • A head-to-head randomized trial found velaglucerase alfa produced hematologic and organ-volume responses comparable to imiglucerase. [2]
  • Patients switched from long-term imiglucerase to velaglucerase alfa maintained stable disease parameters, supporting interchangeable maintenance therapy. [3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study — Gonzalez DE et al., American Journal of Hematology 2013. (Randomized double-blind Phase 3 trial)
  • [2] Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease — Ben Turkia H et al., American Journal of Hematology 2013. (Randomized head-to-head Phase 3 trial)
  • [3] Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase — Zimran A et al., American Journal of Hematology 2013. (Open-label switch trial)
  • [4] Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience — Zimran A et al., Blood 2010. (Phase 1/2 with long-term extension)
  • [5] Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up — Elstein D et al., Blood Cells, Molecules and Diseases 2014. (Long-term follow-up study)
  • [6] Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials — Elstein D et al., Molecular Genetics and Metabolism 2017. (Phase 3 biomarker analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In the pivotal trials velaglucerase alfa was given as an intravenous infusion of 60 units/kg once every other week for treatment-naive patients, with maintenance doses individualized to response.

This describes how the drug was studied and is context only; Gaucher disease ERT must be prescribed and titrated by a specialist.

Side effects & safety profile

Velaglucerase alfa is generally well tolerated; the most common adverse reactions are infusion-related reactions such as headache, dizziness, fever, and back or joint pain.

Anti-drug antibodies develop less frequently than with earlier products, and clinically significant hypersensitivity is uncommon.

As with all enzyme replacement infusions, reactions can occur and treatment should be given with appropriate monitoring, particularly during the first infusions.

Stacking & combinations

It is a physician-administered rare-disease biologic given as monotherapy for the enzyme deficiency, not a compound used in combination stacks.

Finding Velaglucerase alfa vendors

Finding Velaglucerase alfa vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is an enzyme replacement therapy for type 1 (non-neuronopathic) Gaucher disease, replacing the deficient enzyme glucocerebrosidase.

References

  1. [1] Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study — Gonzalez DE et al., American Journal of Hematology 2013. PMID: 23386328. View sourceStudy: Randomized double-blind Phase 3 trialVelaglucerase alfa improved hemoglobin, platelets and organ volumes in treatment-naive type 1 Gaucher disease.
  2. [2] Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease — Ben Turkia H et al., American Journal of Hematology 2013. PMID: 23400823. View sourceStudy: Randomized head-to-head Phase 3 trialVelaglucerase alfa gave hematologic and organ responses comparable to imiglucerase.
  3. [3] Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase — Zimran A et al., American Journal of Hematology 2013. PMID: 23339116. View sourceStudy: Open-label switch trialPatients switched from imiglucerase maintained stable disease parameters on velaglucerase alfa.
  4. [4] Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience — Zimran A et al., Blood 2010. PMID: 20299511. View sourceStudy: Phase 1/2 with long-term extensionLong-term velaglucerase alfa produced sustained improvements in hematologic and organ parameters.
  5. [5] Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up — Elstein D et al., Blood Cells, Molecules and Diseases 2014. PMID: 24581483. View sourceStudy: Long-term follow-up studyVelaglucerase alfa was associated with reduced bone marrow burden over 7 years.
  6. [6] Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naive and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease: Data from phase 3 clinical trials — Elstein D et al., Molecular Genetics and Metabolism 2017. PMID: 28851512. View sourceStudy: Phase 3 biomarker analysisVelaglucerase alfa lowered the Gaucher biomarker lyso-Gb1 in both naive and previously treated patients.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.